Product Reports Resources Pricing Login Book a demo

F2G

Biotech & Life Sciences · Manchester, United Kingdom · Founded 1998

Discovers and develops novel drugs for the treatment of life-threatening fungal diseases

Investors

18 investors on F2G's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
K Nominees
Merifin Capital
Astellas Venture
BankInvest
Series B+ 14 investors entered at this stage
Heartcore Capital
Novartis Venture Fund
Aisling Capital
Morningside
AMR Action Fund
Novo Holdings
Forbion Capital Partners
Sectoral Asset Management
Intermediate Capital Group
The University of Manchester
Sofinnova Partners
Cowen Group
Advent Life Sciences
Brace Pharma

Ownership

Who owns F2G

Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.

21.8% Novo Holdings A/S

Some investors are hidden on this public profile. See the full cap table on Dealroom →

Global footprint

Where F2G has talent and traffic

Workforce by country
6 countries with
team presence
🇬🇧 United Kingdom46.2%
🇺🇸 United States41%
🇦🇹 Austria6%
🇨🇭 Switzerland3%
🇹🇷 Turkey3%
Top 5 of 6 shown
Web traffic by country
1.8K monthly visits
across markets
🇺🇸 United States61.1%
🇬🇧 United Kingdom33.3%
🇮🇳 India11.1%
Top 3 markets shown

Talent graph

The shape of F2G's talent

Dealroom maps F2G's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock F2G's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$24M patent portfolio · 9 active families

Estimated portfolio value
$24M
4.8% of valuation · 3.5× smaller than top peer Athenex ($83M)
9 active patent families
Where F2G innovates AcetamideAntifungalFungal diseaseFungicideMedicinal chemistry

Where F2G concentrates vs peers

Each axis is a top-10 topic across F2G and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about F2G

An AI-synthesized read of the highest-engagement posts about F2G on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See F2G on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.